HOOKIPA Phase 1 HB-200 shows 80% disease control with alternating 2-vector; Phase 2 initiated

HOOKIPA Pharma Inc.

Alternating 2-vector HB-202/HB-201 achieved 80% disease control rate vs historical 35-40% for pembrolizumab.
56% of alternating 2-vector patients had target lesion shrinkage vs 38% for single-vector HB-201.
32% on alternating 2-vector had tumor-specific T cells >5% of circulating pool vs 7% on HB-201.
HB-200 well tolerated; only 8.8% grade ≥3 treatment-related side effects, mostly flu-like symptoms.
Phase 2 plans include combos with pembrolizumab; initial results expected H2 2022, randomized trial H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.